Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 140, Issue 7, pp 1117–1124 | Cite as

RETRACTED ARTICLE: SOX2 oncogenes amplified and operate to activate AKT signaling in gastric cancer and predict immunotherapy responsiveness

  • Yajun Tian
  • Xin Jia
  • Shengxiang Wang
  • Yongsheng Li
  • Peng Zhao
  • Da Cai
  • Zequan Zhou
  • Junmin Wang
  • Yi Luo
  • Maosheng DongEmail author
Original Article – Cancer Research

Abstract

Introduction

Gastric cancer is the second leading cause of cancer mortality in the world. Whether the oncogene, amplified on chromosome 3q26, SOX2, a master transcriptional regulator of stemness, operate to drive strong growth phenotype in gastric cancer were unknown.

Materials and methods

The gene expression changes of SOX2 in human gastric cancer tissues compared with non-cancerous tissues was detected using real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis and immunohistochemistry, which identified the gene overexpression of SOX2 in gastric cancer. Moreover, we discovered that SOX2 promoted cancer cell proliferation in vitro/vivo and SOX2 expression correlated with elevated AKT phosphorylation in gastric cancer, while the AKT phosphorylation was required for SOX2’s oncogenic effects. Next, our data point to the usefulness of SOX2 overexpression, as a new predictive marker for responsiveness to trastuzumab.

Conclusion

SOX2 is a commonly activated tumor promoter that activate AKT signaling in gastric cancer and a new predictive marker for targeted therapy.

Keywords

SOX2 HER2 Phosphorylation Therapeutic antibody Oncogene 

Notes

Acknowledgments

We thank Ms. Min Ding, Dr. Yumin Chen, and Dr. Melissa Cruz, of Institute of Shanghai Springermedia, for the critical review of the manuscript. This work was supported by AfterTumor.com (Grant No. CN1299871A).

Conflict of interest

We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, and there is no professional or other personal interest of any nature or kind in any product, service, and/or company that could be construed as influencing the position presented in, or the review of, the manuscript entitled “SOX2 Oncogenes Amplified and Operate to Activate AKT Signaling in Gastric Cancer and Predicts Immunotherapy Responsiveness.”

References

  1. Agus DB et al (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2(2):127–137PubMedGoogle Scholar
  2. Aksoy I et al. (2013) Sox transcription factors require selective interactions with Oct4 and specific transactivation functions to mediate reprogramming. Stem Cells 31(12):2632–2646PubMedGoogle Scholar
  3. Bang Y-J et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697PubMedGoogle Scholar
  4. Bang Y-J et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379(9813):315–321PubMedGoogle Scholar
  5. Bass AJ et al (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41(11):1238–1242PubMedPubMedCentralGoogle Scholar
  6. Burstein HJ (2005) The distinctive nature of HER2-positive breast cancers. N Engl J Med 353(16):1652–1654PubMedGoogle Scholar
  7. Cho H-S et al (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421(6924):756–760PubMedGoogle Scholar
  8. Ferlay J et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893–2917PubMedGoogle Scholar
  9. Franklin MC et al (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5(4):317–328PubMedGoogle Scholar
  10. Fujimoto-Ouchi K et al (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59(6):795–805PubMedGoogle Scholar
  11. Galluzzi L et al (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31(15):1869–1883PubMedGoogle Scholar
  12. Geyer CE et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743PubMedGoogle Scholar
  13. Hussenet T et al (2010) SOX2 is an oncogene activated by recurrent 3q26. 3 amplifications in human lung squamous cell carcinomas. PLoS One 5(1):e8960PubMedPubMedCentralGoogle Scholar
  14. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137–2150PubMedGoogle Scholar
  15. Kim SY et al (2008) Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol 32(1):89–95PubMedGoogle Scholar
  16. Knuefermann C et al (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22(21):3205–3212PubMedGoogle Scholar
  17. Konecny GE et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66(3):1630–1639PubMedGoogle Scholar
  18. Kute T et al (2004) Development of Herceptin resistance in breast cancer cells. Cytometry Part A 57(2):86–93Google Scholar
  19. Levin B et al (2008) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US multi-society task force on colorectal cancer, and the American College of Radiology. CA Cancer J Clin 58(3):130–160PubMedGoogle Scholar
  20. Li YM et al (2004) Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6(5):459–469PubMedGoogle Scholar
  21. Lu Y et al (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93(24):1852–1857PubMedGoogle Scholar
  22. Muthuswamy SK, Gilman M, Brugge JS (1999) Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. Mol Cell Biol 19(10):6845–6857PubMedPubMedCentralGoogle Scholar
  23. Nagy P et al (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65(2):473–482PubMedGoogle Scholar
  24. Paoletti X et al (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer. JAMA 303(17):1729–1737PubMedGoogle Scholar
  25. Park J-G et al (1990) Characteristics of cell lines established from human gastric carcinoma. Cancer Res 50(9):2773–2780PubMedGoogle Scholar
  26. Pauletti G et al (1996) Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13(1):63–72PubMedGoogle Scholar
  27. Price-Schiavi SA et al (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for Herceptin resistance. Int J Cancer 99(6):783–791PubMedGoogle Scholar
  28. Scaltriti M et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99(8):628–638Google Scholar
  29. Schnitt SJ (2001) Breast cancer in the 21st century: neu opportunities and neu challenges. Mod Pathol 14(3):213–218PubMedGoogle Scholar
  30. Therasse P et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216Google Scholar
  31. Tompkins DH et al (2009) Sox2 is required for maintenance and differentiation of bronchiolar Clara, ciliated, and goblet cells. PLoS One 4(12):e8248PubMedPubMedCentralGoogle Scholar
  32. Tompkins DH et al (2011) Sox2 activates cell proliferation and differentiation in the respiratory epithelium. Am J Respir Cell Mol Biol 45(1):101–110PubMedGoogle Scholar
  33. Yuan P et al (2010) Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 5(2):e9112PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Yajun Tian
    • 1
  • Xin Jia
    • 2
  • Shengxiang Wang
    • 1
  • Yongsheng Li
    • 1
  • Peng Zhao
    • 1
  • Da Cai
    • 1
  • Zequan Zhou
    • 1
  • Junmin Wang
    • 1
  • Yi Luo
    • 1
  • Maosheng Dong
    • 1
    Email author
  1. 1.Hangzhou Sanatorium Health Management CenterHangzhouPeople’s Republic of China
  2. 2.Department of General SurgeryThe Second Affiliated Hospital of Soochow UniversitySuzhouPeople’s Republic of China

Personalised recommendations